证券代码：300078 证券简称：思创医惠 公告编号：2025-085 思创医惠科技股份有限公司 关于重大资产出售暨关联交易实施完毕的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"）向苍南县山海数字科技有 限公司（以下简称"山海数科"）出售公司持有的医惠科技有限公司（以下简称 "医惠科技"或"标的公司"）100%股权，根据《上市公司重大资产重组管理办 法》（以下简称"《重组管理办法》"）的规定，上述交易事项构成重大资产重 组（以下简称"本次交易"）。根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）以及《深 圳证券交易所创业板股票上市规则》等法律、法规及规范性文件的相关规定，本 次交易构成关联交易。 公司分别于 2025 年 4 月 28 日、2025 年 5 月 29 日、2025 年 7 月 14 日、2025 年 7 月 30 日召开第六届董事会第五次会议、第六届董事会第七次会议、第六届 董事会第八次会议、2025 年第三次临时股东会，审议通过了与 ...

国金证券股份有限公司 关于 思创医惠科技股份有限公司 重大资产出售暨关联交易实施情况 之 独立财务顾问核查意见 独立财务顾问 二零二五年八月 声明 国金证券股份有限公司接受思创医惠科技股份有限公司董事会的委托，担任 本次思创医惠科技股份有限公司重大资产重组之独立财务顾问。 根据《公司法》《证券法》《重组管理办法》《26 号准则》等法律法规的相 关规定，按照证券行业公认的业务规范，本着诚实守信、勤勉尽责的精神，遵循 独立、客观、公正的原则，在认真审阅相关资料并充分了解本次交易行为的基础 上，本独立财务顾问出具了本核查意见。 本核查意见所依据的文件、材料由本次交易相关各方提供，本次交易相关各 方已承诺所提供文件和材料真实、准确和完整，不存在虚假记载、误导性陈述或 者重大遗漏。本独立财务顾问不承担由此引起的任何风险责任。 本独立财务顾问未委托或授权其他任何机构或个人提供未在本核查意见中 列载的信息和对本核查意见做任何解释或说明。 本核查意见不构成对思创医惠科技股份有限公司的任何投资建议或意见，本 独立财务顾问对投资者根据本核查意见作出的投资决策可能产生的风险，不承担 任何责任。本独立财务顾问特别提请广大投资者认真阅 ...

思创医惠科技股份有限公司 重大资产出售暨关联交易实施情况 报告书 独立财务顾问 二零二五年八月 上市公司声明 本公司及全体董事、监事、高级管理人员保证本报告书的内容真实、准确和 完整，并对本报告书的虚假记载、误导性陈述或者重大遗漏承担相应的法律责任。 本次重大资产重组的交易对方已出具承诺函，保证其为本次重大资产重组所 提供的信息不存在虚假记载、误导性陈述或者重大遗漏，并对所提供信息的真实 性、准确性和完整性承担相应的法律责任。 本次交易有关监管部门对本次交易事项所作的任何决定或意见，均不代表其 对本公司股票的价值或投资者收益的实质性判断或保证。任何与之相反的声明均 属虚假不实陈述。 本次交易完成后，公司经营与收益的变化由公司负责；因本次交易引致的投 资风险，由投资者自行负责。 投资者若对本报告书存在任何疑问，应咨询自己的股票经纪人、律师、专业 会计师、或其他专业顾问。 1 | 目录 | | --- | | 上市公司声明 1 | | --- | | 目录 2 | | 释义 3 | | 第一节 本次交易概况 5 | | 一、本次交易方案概述 5 | | 二、标的资产的评估及作价情况 5 | | 三、本次交易的性质 ...

北京德恒（杭州）律师事务所 关于 思创医惠科技股份有限公司 重大资产出售暨关联交易实施情况的 法律意见 浙江省杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 电话：0571-86508080 传真：0571-87357755 邮编：310020 | 一、 | 本次交易的方案 4 | | --- | --- | | 二、 | 本次交易的批准和授权 6 | | 三、 | 本次交易的实施过程 7 | | 四、 | 相关实际情况与此前披露的信息是否存在差异 8 | | 五、 | 董事、监事、高级管理人员的更换情况 8 | | 六、 | 本次交易实施过程中资金占用及关联担保的情形 9 | | 七、 | 本次交易相关协议及承诺的履行情况 9 | | 八、 | 本次交易的后续事项 9 | | 九、 | 结论意见 10 | 北京德恒（杭州）律师事务所 关于思创医惠科技股份有限公司 重大资产出售暨关联交易实施情况的法律意见 1.为出具本法律意见，本所律师对公司提供的与本次重大资产重组有关的文 件资料内容的真实性、准确性、完整性进行了审慎的核查和验证，就有关事项询 问了公司的相关人员并进行了必要的讨论。公司已向本 ...

Group 1 - The core viewpoint of the articles highlights the increasing trend of state-owned enterprises (SOEs) in the Yangtze River Delta region engaging in mergers and acquisitions (M&A) to promote local industrial integration and development, shifting from financial investments to deep industrial integration [1][2][3] - In 2025, there have been 17 cases of SOEs directly or indirectly participating in the acquisition of A-share listed companies, with over half of the targets in the machinery, electronics, petrochemicals, and computer sectors, indicating a focus on regional resource optimization and industrial collaboration [1][2] - The current wave of M&A is driven by local governments' strategies to enhance industrial clusters, aiming to strengthen, supplement, and extend the industrial chains [1][2][3] Group 2 - SOEs are utilizing specialized M&A funds to strategically invest in or take control of "chain leader" companies, thereby enhancing local industries and releasing synergistic effects [2][3] - A notable example is the strategic investment by a Shanghai biomedical M&A fund in MicroPort Medical, which aims to support the development of the biomedical sector and attract talent and technological breakthroughs [2][3] - The trend of cross-provincial acquisitions is evident, with SOEs from Jiangsu, Anhui, and Zhejiang acquiring companies in Guangdong and Chongqing, showcasing an upgraded model of "capital attraction + industrial attraction" [5][6] Group 3 - The integration of high-quality scientific and technological assets into SOEs through M&A not only facilitates strategic upgrades for these companies but also optimizes the industrial layout for local SOEs [6] - Data indicates that most of the listed companies acquired by SOEs in the Yangtze River Delta this year have market values below 10 billion yuan, with 10 companies valued under 5 billion yuan and 7 between 5 billion and 10 billion yuan [5][7] - The approach of using M&A as a tool for local industrial development serves as a model for other regions, promoting resource integration and enhancing local industrial chains [3][5]

浙江证监局官网8月1日发布的行政监管措施公告显示，天健会计师事务所（特殊普通合伙）（以下简称"天健所"）及注册会计师廖屹峰、蒋重阳被采取监管 谈话措施。 | 索 引 号 | bm56000001/2025-00009221 | 分 | 行政监管 | | --- | --- | --- | --- | | 发布机构 | | 发文日期 | 2025年 | | श | 关于对天健会计师事务所（特殊普通合伙）及注册会计师廖屹峰、蒋重阳采取监管谈话措施的决定 | | | | 文 물 | | 主题词 | | 三、部分审计底稿记录表述不一致 上述行为不符合《中国注册会计师审计准则第1131号——审计工作底稿》（2016年修订）第八条的规定。 浙江证监局指出，以上行为违反了中国注册会计师执业准则等有关要求，违反了《上市公司信息披露管理办法》（证监会令第182号）第四十五条、第四十 六条的规定。廖屹峰、蒋重阳作为签字注册会计师对上述相关行为应承担主要责任。 天健所质量控制负责人及签字注册会计师廖屹峰、蒋重阳被要求于 2025年8月8日下午2时携带有效身份证件到浙江证监局接受监管谈话。 经查，天健所及两名注册会计师在执行 浙江富 ...

Market Performance - As of August 1, the DRG/DIP concept increased by 1.87%, ranking second among concept sectors, with 19 stocks rising, including Saily Medical, Sichuang Medical, and Jiayuan Technology, which rose by 6.20%, 5.04%, and 5.00% respectively [1] - The top-performing concept sectors included Animal Vaccines at 2.22% and BC Batteries at 1.71%, while the worst performers included the China Shipbuilding System at -2.54% and Military Equipment Restructuring at -1.90% [2] Capital Flow - The DRG/DIP concept sector saw a net inflow of 109 million yuan, with 14 stocks receiving net inflows, and 10 stocks exceeding 10 million yuan in net inflow, led by Weining Health with a net inflow of 93.03 million yuan [2] - Other notable net inflows included Saily Medical at 33.50 million yuan, Rongke Technology at 31.92 million yuan, and Sichuang Medical at 30.87 million yuan [2] Stock Performance - The top stocks in the DRG/DIP concept based on net capital inflow included Weining Health with a 3.31% increase and a turnover rate of 9.45%, followed by Saily Medical at 6.20% and a turnover rate of 25.56% [3] - Other significant performers included Rongke Technology at 2.31% and Sichuang Medical at 5.04%, with respective net inflow ratios of 6.05% and 5.47% [3][4]

Group 1: Market Overview - The A-share market opened lower but saw a recovery, with all three major indices turning positive during the session [1] - The Shanghai Composite Index rose by 1.37 points, or 0.04%, closing at 3574.58 [2] - The Shenzhen Component Index increased by 48.46 points, or 0.44%, closing at 11058.23 [2] - The Northbound 50 Index rose by 3.77 points, or 0.27%, closing at 1426.65 [2] Group 2: Sector Movements - The polysilicon and silicon wafer sectors experienced significant upward movement, with Shuangliang Energy hitting the daily limit [5][6] - Other companies in the polysilicon sector, such as Daqo New Energy, Huamin Co., Tongwei Co., TCL Zhonghuan, and Hongyuan Green Energy, also saw notable gains [6] - The futures contract for polysilicon rose after previously declining over 4%, following the Ministry of Industry and Information Technology's release of a special energy-saving inspection task list for the polysilicon industry [7] Group 3: Innovation Drug Sector - The innovative drug sector continued to rise, with companies like Shuyou Shen, Rejing Bio, Kangchen Pharmaceutical, and Fuyuan Pharmaceutical reaching historical highs [8] - The FDA accepted the listing application for HSK3486 (环泊酚注射液) from Haishi Ke, and Huahai Pharmaceutical received approval for a dual-target drug [8] - Analysts noted that the innovative drug sector remains a core direction for the pharmaceutical industry, supported by policies and increasing global competitiveness [8] Group 4: Real Estate Sector - Dalian City Real Estate surged over 40% after announcing plans for privatization and delisting from the Hong Kong Stock Exchange [14][15] - The company proposed a buyback of shares at HKD 0.62 per share, totaling approximately HKD 29.32 billion [17] - NIO's stock rose over 9% following the launch of its new L90 model, which offers various seating configurations and competitive pricing [17] Group 5: Logistics Sector - The logistics sector saw significant gains, with companies like Shentong Express and Yunda Holdings hitting the daily limit [9][13] - The National Postal Administration held a meeting to address issues in the industry and promote high-quality development [13]

Group 1 - The assisted reproductive industry is experiencing a strong upward trend, with companies such as HanShang Group, FuYuan Pharmaceutical, and LiDeMan reaching their daily price limit [1] - Other companies in the sector, including GongTong Pharmaceutical, DaJia WeiKang, SiChuang YiHui, BoTuo Bio, BeiRui Gene, and MaiDi Technology, also saw significant increases in their stock prices [1]

辅助生殖概念持续走强，汉商集团、福元医药、利德曼涨停，共同药业、达嘉维康、思创医惠、博拓生 物、贝瑞基因、麦迪科技等跟涨。 ...